Dechow A, Timonen S, Ianevski A, Jiang Q, Wahnschaffe L, Peng Y, Jungherz D, Becker K, Neubauer HA, Schönefeldt S, de Araujo E, Gunning P, Fleck R, Schrader A, Hallek M, Pflug N, Moriggl R, Aittokallio T, Mustjoki S, Braun T, Herling M(2025) Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia Leukemia(in press) DOI 10.1038/s41375-025-02577-8, PubMed 40234614
Tanoli Z, Fernández-Torras A, Özcan UO, Kushnir A, Nader KM, Gadiya Y, Fiorenza L, Ianevski A, Vähä-Koskela M, Miihkinen M, Seemab U, Leinonen H, Seashore-Ludlow B, Tampere M, Kalman A, Ballante F, Benfenati E, Saunders G, Potdar S, Gómez García I, García-Serna R, Talarico C, Beccari AR, Schaal W, Polo Aet al.(2025) Computational drug repurposing: approaches, evaluation of in silico resources and case studies Nat Rev Drug Discov(in press) DOI 10.1038/s41573-025-01164-x, PubMed 40102635
Yin Y, Xu H, He L, Brown JR, Mato AR, Aittokallio T, Skånland SS(2025) Protein profiles predict treatment responses to the PI3K inhibitor umbralisib in patients with chronic lymphocytic leukemia Clin Cancer Res(in press) DOI 10.1158/1078-0432.CCR-24-2911, PubMed 40085050
